Amarin Corp. (AMRN) Gets U.S. Patent for AMR101
Amarin Corporation plc (Nasdaq: AMRN), reports that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's AMR101 based on U.S. Patent Application Serial No. 12/052,598, also known as the EPA with no DHA in a capsule application. Amarin announced on March 20, 2012, the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,188,146, is titled "Highly Purified Ethyl EPA and Other EPA Derivatives."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Therapeutics (VKTX) Presents Data from VK0214 POC Study in X-ALD; Primary Objective Achieved
- Idera Pharma (IDRA) Updates on IMO-2125 Phase 1/2 in Metastatic Melanoma; Promising Data Noted
- Onconova Therapeutics (ONTX) Completes End-of-Phase 2 Meeting w/ FDA for Oral Rigosertib and Azacitidine
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!